Sandip Sabharwal of Prabhudas Lilladher told CNBC-TV18, "Ranbaxy Laboratories has turned into a stock where most investors including us have typically avoided the stock. What has been coming out of the company in terms of what the management says and what actually comes out later, there is a huge difference between the two."
"I think it is better to avoid this stock at any given price at this point of time till more clarity comes and focus on the companies which are actually doing well," he added. Also Read: Adulterated drugs: SC dismisses PIL against Ranbaxy
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
